drugset

drugset / Trial / NCT03244072

Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

NCT03244072 ↗

Phase 2/3 Not yet recruiting 60000 enrolled Jason Ahee, M.D.

RandomizedParallel-groupTriple-blindPrevention

Summary

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

Timeline

Start: 2026-06-01
Primary completion: 2030-10
Completion: 2031-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Moxifloxacin	Small molecule	0.1 %	Other

Indications